Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Hank Nordhoff to Retire from Gen-Probe's Board; Rheonix Expands Management Team

Premium

Gen-Probe said this week that Hank Nordhoff, chairman of its board, plans to retire at the end of 2011.

The board has elected Carl Hull, Gen-Probe's president and CEO, to succeed him as chairman.

Nordhoff was president and CEO of the company from 1994 through 2009 and non-executive chairman of the board since that time. He will serve as a consultant to the board until the end of 2012.

Hull joined Gen-Probe in 2007 as executive vice president and chief operating officer and was promoted to president in 2008 and to CEO in 2009.


Rheonix has appointed Tom Karpen as vice president of operations and Terry Howell as quality manager.

The company said Karpen and Howell will help it commercialize its CARD (Chemistry and Reagent Device) automated microfluidics platform for diagnostic applications.

Before joining Rheonix, Karpen managed R&D, quality, and production engineering teams for GE Inspection Technologies and served as director of engineering at Everest-VIT. He has a BA in physics from the State University of New York, Geneseo, and a BS in electrical and computer engineering from Clarkson University.

Howell comes from Percivia, where he directed bioassay lab operations and developed quality systems. He also managed bioassay quality control at Stryker Biotech. He has a BS in animal science from Virginia Tech and an MBA from Northeastern University.

The Scan

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.